

Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	4	6.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	2.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	8	6.6	122.1	(52.6-240.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	1	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	0.4	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	5	3.0	166.1	(53.5-387.5)	Female	13	19.5	66.8	(35.5-114.2)
Female	2	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.5	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	24	21.7	110.8	(71.0-164.9)	Female	2	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	8.2	85.1	(34.1-175.3)	Female	3	2.2	nc	(nc-nc)
Female	11	6.6	167.6	(83.5-299.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.6	nc	(nc-nc)	Male	19	22.0	86.4	(52.0-134.9)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.0	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.0	nc	(nc-nc)	Male	62	79.3	78.2	(60.0-100.3)
Female	0	0.2	nc	(nc-nc)	Female	80	70.8	112.9	(89.5-140.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	1.5	nc	(nc-nc)	Male	62	79.3	78.2	(60.0-100.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.5	nc	(nc-nc)	Female	80	70.8	112.9	(89.5-140.6)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	5	10.3	48.6	(15.6-113.3)	Male	62	79.3	78.2	(60.0-100.3)
Female	15	8.8	170.4	(95.3-281.1)	Female	80	70.8	112.9	(89.5-140.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	43.4	115.3	(85.6-152.0)	Male	26	26.9	96.7	(63.1-141.7)
Female	18	17.6	102.2	(60.6-161.6)	Female	25	24.4	102.5	(66.3-151.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	8.1	61.6	(19.8-143.7)	Male	4	6.7	nc	(nc-nc)
Female	3	7.5	nc	(nc-nc)	Female	7	5.6	125.0	(50.1-257.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.4	nc	(nc-nc)	Male	33	23.0	143.3	(98.6-201.3)
Female	167	167.9	99.5	(84.9-115.7)	Female	22	22.9	96.1	(60.2-145.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	7.4	135.0	(64.6-248.2)	Male	16	16.1	99.1	(56.6-160.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	59	60.5	97.6	(74.3-125.8)	Female	16	17.7	90.2	(51.5-146.5)
Female	75	64.3	116.7	(91.8-146.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	13.0	76.8	(36.8-141.3)
Male	12	11.1	107.8	(55.6-188.3)	Female	22	15.2	144.4	(90.5-218.6)
Female	6	3.4	175.6	(64.1-382.2)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	138	160.3	86.1	(72.3-101.7)
Male	4	3.8	nc	(nc-nc)	<u>Stomach</u>				
Female	3	3.4	nc	(nc-nc)	Male	17	10.0	170.2	(99.1-272.5)
<u>Kidney & Renal Pelvis</u>					Female	9	7.0	127.8	(58.3-242.6)
Male	17	20.2	84.2	(49.0-134.9)	<u>Testis</u>				
Female	10	13.8	72.3	(34.6-133.0)	Male	4	6.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	10	6.9	145.3	(69.5-267.2)	Male	10	6.9	144.9	(69.4-266.6)
Female	2	2.0	nc	(nc-nc)	Female	24	23.6	101.6	(65.1-151.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	23	14.3	160.5	(101.7-240.8)	Female	26	37.3	69.8	(45.6-102.2)
Female	15	12.4	120.9	(67.6-199.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	605	572.5	105.7	(97.4-114.4)
Male	6	9.9	60.8	(22.2-132.3)	Female	648	597.8	108.4	(100.2-117.1)
Female	4	3.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	107	80.1	133.7	(109.5-161.5)					
Female	104	84.1	123.7	(101.0-149.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	8.6	138.9	(71.7-242.6)	Male	4	5.7	nc	(nc-nc)
Female	7	3.0	232.5	(93.1-479.0)	Female	3	4.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.7	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	25	32.3	77.3	(50.0-114.1)	Female	5	4.0	124.3	(40.0-290.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.4	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	12.5	104.1	(55.4-178.0)	Female	1	3.3	nc	(nc-nc)
Female	12	10.7	112.2	(57.9-196.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	4	2.4	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	34	35.2	96.6	(66.9-134.9)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	7	4.4	160.1	(64.1-329.8)	Male	0	2.0	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	6	1.5	397.0	(145.0-864.1)	Male	2	1.3	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	2.9	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	2	4.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.2	nc	(nc-nc)	Female	5	7.4	67.5	(21.7-157.4)
Female	1	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	21	16.4	127.9	(79.1-195.5)	Male	131	120.7	108.5	(90.7-128.7)
Female	29	15.1	192.5	(128.9-276.4)	Female	121	108.9	111.1	(92.2-132.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	3	5.7	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	8	19.6	40.9	(17.6-80.5)
Male	0	0.3	nc	(nc-nc)	Female	6	11.8	50.9	(18.6-110.7)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	2.9	nc	(nc-nc)					
Female	1	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	23.7	139.2	(95.8-195.5)	Male	24	14.5	165.3	(105.9-246.0)
Female	10	8.5	117.8	(56.4-216.6)	Female	19	11.8	161.6	(97.2-252.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	4.4	203.9	(93.0-387.1)	Male	9	3.7	244.3	(111.5-463.8)
Female	6	3.7	163.3	(59.6-355.5)	Female	2	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	15	12.5	119.8	(67.0-197.7)
Female	100	84.4	118.5	(96.4-144.1)	Female	9	11.1	81.4	(37.1-154.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.6	nc	(nc-nc)	Male	7	8.9	78.6	(31.5-162.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	34	33.1	102.8	(71.2-143.7)	Female	14	8.7	160.1	(87.4-268.6)
Female	23	31.0	74.3	(47.1-111.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	7.1	154.1	(76.8-275.8)
Male	5	6.1	81.7	(26.3-190.7)	Female	8	7.3	108.9	(46.9-214.5)
Female	1	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	119	86.6	137.4	(113.8-164.4)
Male	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.5	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	3.4	nc	(nc-nc)
Male	15	11.0	135.9	(76.0-224.1)	<u>Testis</u>				
Female	6	6.8	88.3	(32.2-192.1)	Male	4	3.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	3.8	213.3	(91.8-420.3)	Male	4	3.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	7	11.5	61.0	(24.4-125.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	7.8	141.6	(70.6-253.4)	Female	15	18.6	80.8	(45.2-133.2)
Female	10	6.0	166.5	(79.7-306.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	377	310.5	121.4	(109.5-134.3)
Male	4	5.4	nc	(nc-nc)	Female	306	293.2	104.4	(93.0-116.8)
Female	2	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	42	43.7	96.0	(69.2-129.8)					
Female	33	40.9	80.6	(55.5-113.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	48	36.9	130.0	(95.9-172.4)	Male	17	21.7	78.4	(45.6-125.5)
Female	13	13.5	96.1	(51.1-164.4)	Female	15	17.2	87.1	(48.7-143.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.2	80.4	(25.9-187.7)	Male	6	5.7	105.5	(38.5-229.5)
Female	6	5.3	113.0	(41.3-246.0)	Female	4	4.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	25	18.7	133.9	(86.7-197.7)
Female	133	127.0	104.7	(87.7-124.1)	Female	27	17.2	156.9	(103.3-228.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.1	nc	(nc-nc)	Male	16	13.4	119.8	(68.4-194.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	51	50.9	100.2	(74.6-131.7)	Female	10	13.3	75.1	(36.0-138.2)
Female	53	48.5	109.3	(81.9-143.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	11.1	90.2	(43.2-165.8)
Male	8	9.5	84.5	(36.4-166.5)	Female	11	11.6	94.7	(47.2-169.4)
Female	3	2.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	130	138.2	94.1	(78.6-111.7)
Male	1	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	2.0	nc	(nc-nc)	Male	9	8.4	107.4	(49.0-203.8)
<u>Kidney & Renal Pelvis</u>					Female	3	5.2	nc	(nc-nc)
Male	22	16.7	131.6	(82.5-199.3)	<u>Testis</u>				
Female	11	10.6	104.2	(51.9-186.4)	Male	5	3.9	128.1	(41.3-299.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	5.9	102.3	(37.3-222.6)	Male	8	5.1	155.9	(67.1-307.3)
Female	1	1.6	nc	(nc-nc)	Female	18	15.8	113.8	(67.4-179.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	11.5	87.1	(41.7-160.3)	Female	36	28.9	124.4	(87.1-172.2)
Female	9	9.0	100.4	(45.8-190.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	511	479.5	106.6	(97.5-116.2)
Male	13	8.2	158.4	(84.2-270.8)	Female	476	449.3	105.9	(96.6-115.9)
Female	1	2.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	78	68.4	114.0	(90.1-142.3)					
Female	75	65.6	114.3	(89.9-143.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	3	3.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	12	11.2	107.0	(55.2-187.0)
Male	0	0.2	nc	(nc-nc)	Female	9	8.7	103.9	(47.4-197.2)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	1.5	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	22.8	92.1	(57.0-140.8)	Male	27	14.0	192.8	(127.0-280.5)
Female	5	8.3	60.0	(19.3-140.0)	Female	19	11.1	170.6	(102.7-266.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.1	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	8	11.9	67.1	(28.9-132.2)
Female	81	82.6	98.0	(77.8-121.8)	Female	9	10.7	83.9	(38.3-159.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.4	nc	(nc-nc)	Male	14	8.9	157.0	(85.8-263.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	32.1	96.7	(65.7-137.2)	Female	5	8.5	58.5	(18.9-136.6)
Female	31	29.7	104.2	(70.8-147.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	7.0	nc	(nc-nc)
Male	5	6.1	82.0	(26.4-191.3)	Female	5	7.1	70.2	(22.6-163.9)
Female	3	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	101	90.6	111.4	(90.8-135.4)
Male	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
Female	4	1.3	nc	(nc-nc)	Male	6	5.2	115.6	(42.2-251.6)
<u>Kidney & Renal Pelvis</u>					Female	4	3.2	nc	(nc-nc)
Male	10	11.0	91.2	(43.7-167.7)	<u>Testis</u>				
Female	4	6.7	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.8	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	12	10.7	112.7	(58.2-196.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	7.3	68.8	(22.2-160.5)	Female	17	18.8	90.5	(52.7-145.0)
Female	10	5.7	176.1	(84.3-323.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	339	307.5	110.3	(98.8-122.6)
Male	4	5.4	nc	(nc-nc)	Female	282	285.4	98.8	(87.6-111.0)
Female	2	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	49	43.3	113.1	(83.7-149.5)					
Female	33	40.8	80.9	(55.7-113.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	15.9	125.5	(76.6-193.8)	Male	13	10.1	129.1	(68.7-220.8)
Female	4	5.2	nc	(nc-nc)	Female	4	7.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.0	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	8	8.6	93.2	(40.1-183.7)
Female	73	55.4	131.7	(103.2-165.6)	Female	7	7.0	100.5	(40.2-207.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.4	nc	(nc-nc)	Male	7	6.4	109.2	(43.8-225.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	22.6	92.7	(57.4-141.8)	Female	4	5.7	nc	(nc-nc)
Female	15	18.8	79.6	(44.5-131.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	4.3	nc	(nc-nc)	Male	54	62.4	86.5	(65.0-112.9)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	3	1.2	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	7.8	103.2	(44.4-203.3)	Female	12	12.3	97.3	(50.2-170.0)
Female	5	4.4	114.5	(36.9-267.1)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.7	nc	(nc-nc)	Male	208	216.1	96.3	(83.6-110.3)
Female	0	0.7	nc	(nc-nc)	Female	205	187.7	109.2	(94.8-125.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	5.2	134.7	(53.9-277.4)	<u>All Sites / Types</u>				
Female	4	3.7	nc	(nc-nc)	Male	208	216.1	96.3	(83.6-110.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	3.9	nc	(nc-nc)	Female	205	187.7	109.2	(94.8-125.3)
Female	2	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	27	30.0	89.9	(59.2-130.8)	Male	208	216.1	96.3	(83.6-110.3)
Female	30	26.0	115.5	(77.9-164.8)	Female	205	187.7	109.2	(94.8-125.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	17.3	115.6	(70.6-178.6)	Male	15	11.6	129.2	(72.3-213.2)
Female	2	5.9	nc	(nc-nc)	Female	20	9.3	214.7	(131.1-331.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.6	165.4	(60.4-360.1)	Male	2	2.8	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	5	1.9	259.3	(83.6-605.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	19	9.8	193.3	(116.3-301.8)
Female	79	68.1	116.0	(91.8-144.6)	Female	6	8.1	74.3	(27.1-161.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.0	nc	(nc-nc)	Male	4	7.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	25.3	67.1	(39.1-107.5)	Female	6	6.8	87.6	(32.0-190.7)
Female	24	21.8	110.3	(70.7-164.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	5.4	129.0	(51.7-265.8)
Male	7	4.8	144.8	(58.0-298.4)	Female	11	5.1	214.1	(106.7-383.2)
Female	2	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	61	69.6	87.6	(67.0-112.5)
Male	2	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.1	nc	(nc-nc)	Male	6	4.0	148.2	(54.1-322.6)
<u>Kidney & Renal Pelvis</u>					Female	1	2.3	nc	(nc-nc)
Male	1	9.0	nc	(nc-nc)	<u>Testis</u>				
Female	8	5.1	155.7	(67.0-306.7)	Male	2	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.0	nc	(nc-nc)	Male	7	3.1	225.4	(90.3-464.5)
Female	0	0.8	nc	(nc-nc)	Female	21	9.7	216.5	(134.0-330.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	6.0	100.7	(36.8-219.1)	Female	15	14.9	100.5	(56.2-165.8)
Female	5	4.4	113.0	(36.4-263.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	234	242.4	96.5	(84.6-109.7)
Male	4	4.5	nc	(nc-nc)	Female	261	223.1	117.0	(103.2-132.1)
Female	1	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	24	32.8	73.1	(46.8-108.8)					
Female	27	29.4	91.7	(60.4-133.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.6	109.4	(35.3-255.4)	Male	3	2.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	15	15.0	99.9	(55.9-164.7)	Female	1	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	6.4	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
Female	5	5.3	94.5	(30.4-220.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.4	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	15	17.7	85.0	(47.5-140.2)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.6	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.4	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	54	60.5	89.3	(67.1-116.5)
Male	2	1.0	nc	(nc-nc)	Female	43	51.7	83.1	(60.2-112.0)
Female	0	0.3	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	9	8.6	105.1	(48.0-199.6)	<u>Bladder, Urinary</u>				
Female	7	7.5	93.2	(37.4-192.1)	Male	5	4.6	109.4	(35.3-255.4)
					Female	1	1.5	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	3.0	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	8	10.7	74.5	(32.1-146.7)	Female	1	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	4.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	5	4.7	106.8	(34.4-249.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	11	11.1	98.9	(49.3-176.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.4	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Male	29	38.6	75.1	(50.3-107.8)
Female	1	0.1	nc	(nc-nc)	Female	31	39.4	78.8	(53.5-111.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.8	nc	(nc-nc)	Male	29	38.6	75.1	(50.3-107.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	31	39.4	78.8	(53.5-111.8)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	3	5.5	nc	(nc-nc)	Male	29	38.6	75.1	(50.3-107.8)
Female	3	5.6	nc	(nc-nc)	Female	31	39.4	78.8	(53.5-111.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.7	106.4	(34.3-248.3)	Male	4	3.1	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	26	17.2	151.2	(98.7-221.6)	Female	2	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	6.9	116.5	(50.2-229.6)	Female	1	1.7	nc	(nc-nc)
Female	6	5.2	114.8	(41.9-250.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	2.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	1.6	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	1.2	nc	(nc-nc)	Female	6	3.9	154.7	(56.5-336.7)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	2	9.0	nc	(nc-nc)	Female	69	65.8	104.9	(81.6-132.7)
Female	6	7.3	82.3	(30.0-179.1)	Female	63	55.3	113.9	(87.5-145.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.4	93.6	(34.2-203.7)	Male	3	4.9	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.6	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	20	22.4	89.4	(54.6-138.1)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	9.6	93.5	(42.7-177.5)	Female	1	2.3	nc	(nc-nc)
Female	7	7.4	94.7	(37.9-195.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.8	nc	(nc-nc)	Male	32	26.1	122.4	(83.7-172.8)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.6	nc	(nc-nc)	Female	3	4.9	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.1	nc	(nc-nc)	Male	104	94.6	110.0	(89.9-133.3)
Female	0	0.3	nc	(nc-nc)	Female	65	75.2	86.4	(66.7-110.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	1.5	nc	(nc-nc)	Male	104	94.6	110.0	(89.9-133.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.7	nc	(nc-nc)	Female	65	75.2	86.4	(66.7-110.2)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	18	12.4	145.6	(86.2-230.1)	Male	104	94.6	110.0	(89.9-133.3)
Female	15	10.2	146.7	(82.0-242.0)	Female	65	75.2	86.4	(66.7-110.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	34.3	99.1	(68.6-138.5)	Male	20	22.0	90.8	(55.4-140.2)
Female	17	12.9	132.1	(76.9-211.5)	Female	11	18.4	59.8	(29.8-107.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	6.8	118.2	(50.9-232.9)	Male	7	5.4	128.8	(51.6-265.4)
Female	6	5.7	105.2	(38.4-228.9)	Female	4	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.1	nc	(nc-nc)	Male	16	18.8	85.3	(48.7-138.5)
Female	115	127.5	90.2	(74.5-108.3)	Female	19	16.8	112.9	(67.9-176.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.9	nc	(nc-nc)	Male	5	13.5	37.1	(12.0-86.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	41	48.7	84.3	(60.5-114.3)	Female	9	13.3	67.8	(31.0-128.8)
Female	51	47.0	108.6	(80.9-142.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	9.0	nc	(nc-nc)	Male	111	129.1	85.9	(70.7-103.5)
Female	1	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	5	3.0	168.8	(54.4-393.9)	Male	7	5.3	131.9	(52.9-271.9)
Female	4	2.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	16.6	72.3	(37.3-126.3)	Female	27	28.1	96.1	(63.3-139.8)
Female	6	10.3	58.2	(21.3-126.8)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	4	5.6	nc	(nc-nc)	Male	5	11.6	43.2	(13.9-100.7)
Female	3	1.5	nc	(nc-nc)	Female	5	9.3	53.9	(17.4-125.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	8	8.1	98.5	(42.4-194.2)	Male	54	63.6	84.9	(63.8-110.8)
Female	1	2.8	nc	(nc-nc)	Female	61	61.6	99.0	(75.7-127.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	7	6.2	113.6	(45.5-234.2)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.4	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	7	5.5	126.7	(50.8-261.1)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.5	nc	(nc-nc)	Female	4	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	17	19.7	86.5	(50.4-138.5)
Male	0	0.4	nc	(nc-nc)	Female	15	18.4	81.6	(45.7-134.6)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	2.5	nc	(nc-nc)					
Female	1	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	28.0	107.1	(72.2-152.9)	Male	8	16.0	50.0	(21.5-98.5)
Female	9	11.1	81.4	(37.1-154.5)	Female	12	12.9	92.8	(47.9-162.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.5	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	14	13.8	101.2	(55.3-169.8)
Female	92	96.6	95.2	(76.8-116.8)	Female	16	13.8	116.0	(66.3-188.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.6	137.6	(44.3-321.0)	Male	12	9.7	123.3	(63.6-215.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	45	38.2	117.6	(85.8-157.4)	Female	13	10.3	126.4	(67.2-216.1)
Female	42	40.1	104.8	(75.6-141.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	8.3	143.9	(74.3-251.4)
Male	8	7.1	113.3	(48.8-223.3)	Female	12	9.6	125.3	(64.7-219.0)
Female	3	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	97	102.7	94.4	(76.6-115.2)
Male	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.4	nc	(nc-nc)	Male	9	6.3	142.0	(64.8-269.5)
<u>Kidney & Renal Pelvis</u>					Female	6	4.4	136.5	(49.8-297.1)
Male	15	12.4	121.2	(67.8-199.9)	<u>Testis</u>				
Female	5	8.3	60.4	(19.5-141.0)	Male	1	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	4.4	114.8	(37.0-267.8)	Male	3	3.7	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	6	11.1	54.0	(19.7-117.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	8.5	129.2	(64.4-231.1)	Female	25	22.0	113.8	(73.6-168.0)
Female	8	7.2	111.4	(48.0-219.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	347	357.7	97.0	(87.1-107.8)
Male	7	6.0	115.9	(46.4-238.8)	Female	346	352.0	98.3	(88.2-109.2)
Female	2	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	43	51.8	83.1	(60.1-111.9)					
Female	44	52.5	83.8	(60.9-112.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	59.3	91.1	(68.4-118.9)	Male	37	40.4	91.5	(64.4-126.1)
Female	25	25.2	99.4	(64.3-146.7)	Female	27	38.8	69.5	(45.8-101.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	12.8	117.4	(65.7-193.7)	Male	5	9.4	53.3	(17.2-124.4)
Female	13	11.5	112.8	(60.0-192.9)	Female	7	7.9	88.6	(35.5-182.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.9	nc	(nc-nc)	Male	32	34.2	93.5	(63.9-132.0)
Female	214	241.1	88.8	(77.3-101.5)	Female	35	33.4	104.8	(73.0-145.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	12.2	90.1	(44.9-161.2)	Male	23	23.2	99.3	(62.9-149.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	80	84.1	95.1	(75.4-118.4)	Female	13	25.8	50.5	(26.9-86.3)
Female	82	91.5	89.7	(71.3-111.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	20	17.8	112.2	(68.5-173.3)
Male	13	15.4	84.6	(45.0-144.6)	Female	13	21.6	60.2	(32.0-102.9)
Female	6	4.9	123.7	(45.2-269.2)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	163	218.5	74.6	(63.6-87.0)
Male	4	8.0	nc	(nc-nc)	<u>Stomach</u>				
Female	9	6.6	135.7	(61.9-257.7)	Male	19	13.9	136.8	(82.4-213.7)
<u>Kidney & Renal Pelvis</u>					Female	13	10.1	128.2	(68.2-219.2)
Male	32	28.8	111.0	(75.9-156.8)	<u>Testis</u>				
Female	8	19.8	40.4	(17.4-79.6)	Male	17	16.0	106.5	(62.0-170.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	13	9.5	136.6	(72.7-233.7)	Male	15	11.8	127.2	(71.1-209.8)
Female	3	2.9	nc	(nc-nc)	Female	40	40.0	100.1	(71.5-136.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	19	21.3	89.3	(53.7-139.4)	Female	48	53.1	90.4	(66.6-119.8)
Female	29	18.4	157.6	(105.5-226.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	753	811.8	92.8	(86.3-99.6)
Male	22	13.9	158.7	(99.4-240.2)	Female	788	871.8	90.4	(84.2-96.9)
Female	6	5.4	110.3	(40.3-240.0)					
<u>Lung and Bronchus</u>									
Male	123	109.4	112.4	(93.4-134.1)					
Female	95	119.7	79.4	(64.2-97.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	22.1	126.4	(84.0-182.7)	Male	7	12.6	55.6	(22.3-114.5)
Female	10	8.8	114.3	(54.7-210.1)	Female	16	11.0	145.7	(83.2-236.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
Female	5	3.5	144.3	(46.5-336.8)	Female	5	2.8	180.5	(58.2-421.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	14	10.9	128.1	(70.0-214.9)
Female	95	77.2	123.1	(99.6-150.5)	Female	11	11.1	99.1	(49.4-177.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.1	nc	(nc-nc)	Male	8	7.6	105.4	(45.4-207.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	30.2	89.5	(59.0-130.2)	Female	14	8.4	167.5	(91.5-281.1)
Female	25	31.8	78.6	(50.9-116.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	6.6	nc	(nc-nc)
Male	7	5.5	126.9	(50.8-261.4)	Female	11	7.6	145.2	(72.4-259.8)
Female	0	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	87	79.3	109.7	(87.9-135.3)
Male	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.7	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	3.5	nc	(nc-nc)
Male	8	9.6	83.0	(35.7-163.5)	<u>Testis</u>				
Female	4	6.6	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	3.4	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	7	10.0	70.2	(28.1-144.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	6.8	nc	(nc-nc)	Female	23	17.4	132.1	(83.7-198.3)
Female	6	5.9	101.5	(37.1-220.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	280	280.0	100.0	(88.6-112.4)
Male	2	4.7	nc	(nc-nc)	Female	297	283.5	104.8	(93.2-117.4)
Female	1	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	46	40.4	113.9	(83.4-151.9)					
Female	32	41.4	77.3	(52.9-109.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.6	89.4	(28.8-208.6)	Male	5	3.9	129.4	(41.7-301.9)
Female	3	2.0	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	20	22.5	88.8	(54.2-137.1)	Female	3	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	8.3	60.3	(19.4-140.8)	Female	3	2.3	nc	(nc-nc)
Female	4	7.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	1.8	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	26	23.0	112.9	(73.7-165.4)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.8	nc	(nc-nc)
Male	0	2.9	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	3.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.9	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	70	79.7	87.8	(68.4-110.9)
Male	0	1.5	nc	(nc-nc)	Female	67	74.2	90.2	(69.9-114.6)
Female	1	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	10.6	56.7	(20.7-123.5)					
Female	7	9.8	71.8	(28.8-147.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.7	117.2	(53.5-222.5)	Male	9	5.6	161.5	(73.7-306.6)
Female	2	2.4	nc	(nc-nc)	Female	5	4.5	112.1	(36.1-261.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.7	107.2	(34.5-250.1)
Female	43	30.8	139.8	(101.2-188.3)	Female	1	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	11.5	130.6	(73.0-215.4)	Female	2	3.0	nc	(nc-nc)
Female	11	8.9	123.4	(61.5-220.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	2.5	203.9	(65.7-475.9)
Male	3	2.2	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	37	32.2	115.0	(80.9-158.5)
Male	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	5	1.8	275.5	(88.8-643.0)
<u>Kidney & Renal Pelvis</u>					Female	1	0.9	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	<u>Testis</u>				
Female	5	2.3	221.8	(71.5-517.6)	Male	0	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	7	5.0	139.4	(55.8-287.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.8	nc	(nc-nc)	Female	7	6.7	104.3	(41.8-215.0)
Female	3	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	124	112.3	110.4	(91.8-131.6)
Male	1	2.1	nc	(nc-nc)	Female	117	98.7	118.6	(98.1-142.1)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	14.8	88.1	(46.9-150.7)					
Female	13	12.4	105.2	(56.0-179.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	18.6	123.7	(78.4-185.7)	Male	11	11.4	96.8	(48.2-173.2)
Female	8	7.6	105.7	(45.5-208.3)	Female	4	9.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.5	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	8	9.8	81.4	(35.1-160.5)
Female	49	68.7	71.4	(52.8-94.4)	Female	10	9.7	102.7	(49.2-188.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.0	nc	(nc-nc)	Male	8	6.8	117.9	(50.8-232.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	25.9	150.8	(107.2-206.1)	Female	6	7.3	82.0	(29.9-178.5)
Female	24	28.0	85.8	(54.9-127.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	4.7	nc	(nc-nc)	Male	42	66.5	63.2	(45.5-85.4)
Female	0	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.6	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	8.5	58.9	(19.0-137.4)	Female	21	15.1	139.1	(86.1-212.7)
Female	4	5.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.9	nc	(nc-nc)	Male	213	241.7	88.1	(76.7-100.8)
Female	2	0.8	nc	(nc-nc)	Female	200	249.8	80.1	(69.4-92.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	6.2	145.0	(66.1-275.2)	<u>All Sites / Types</u>				
Female	6	5.4	112.1	(40.9-244.1)	Male	213	241.7	88.1	(76.7-100.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	4.1	nc	(nc-nc)	Female	200	249.8	80.1	(69.4-92.0)
Female	2	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	26	33.8	77.0	(50.3-112.8)	Male	213	241.7	88.1	(76.7-100.8)
Female	28	35.5	78.9	(52.4-114.0)	Female	200	249.8	80.1	(69.4-92.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.5	84.0	(36.2-165.5)	Male	4	6.3	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	3	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.9	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	9	5.3	168.5	(76.9-319.9)
Female	46	34.6	133.1	(97.5-177.6)	Female	4	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	13.6	132.0	(78.2-208.7)	Female	5	3.6	140.8	(45.4-328.6)
Female	21	12.0	175.6	(108.7-268.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	2.9	171.6	(55.3-400.5)
Male	3	2.5	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	38	35.8	106.2	(75.1-145.7)
Male	3	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	2.2	224.6	(72.4-524.1)
<u>Kidney & Renal Pelvis</u>					Female	2	1.3	nc	(nc-nc)
Male	2	4.7	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.7	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.3	nc	(nc-nc)	Female	8	7.6	104.9	(45.2-206.7)
Female	1	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	138	129.1	106.9	(89.8-126.3)
Male	1	2.3	nc	(nc-nc)	Female	125	118.1	105.9	(88.1-126.2)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	17.6	102.3	(60.6-161.8)					
Female	16	16.2	98.9	(56.5-160.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	12.7	70.8	(32.3-134.5)	Male	7	8.2	85.6	(34.3-176.5)
Female	7	4.3	164.3	(65.8-338.5)	Female	4	6.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	11	7.0	157.8	(78.7-282.4)
Female	40	44.8	89.2	(63.7-121.5)	Female	9	5.7	157.7	(72.0-299.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.0	nc	(nc-nc)	Male	5	5.2	96.8	(31.2-225.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	18.2	132.0	(84.5-196.4)	Female	3	4.6	nc	(nc-nc)
Female	24	15.4	156.1	(100.0-232.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.9	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	39	49.5	78.9	(56.1-107.8)
Male	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.6	nc	(nc-nc)
Male	2	6.2	nc	(nc-nc)	<u>Testis</u>				
Female	7	3.6	196.6	(78.8-405.2)	Male	2	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.1	nc	(nc-nc)	Male	5	2.1	233.0	(75.1-543.8)
Female	0	0.5	nc	(nc-nc)	Female	4	6.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	4.3	nc	(nc-nc)	Female	15	10.0	149.5	(83.6-246.5)
Female	5	3.1	163.0	(52.5-380.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	156	173.4	90.0	(76.4-105.3)
Male	3	3.1	nc	(nc-nc)	Female	168	153.0	109.8	(93.9-127.8)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	24	23.8	100.7	(64.5-149.9)					
Female	24	21.1	113.9	(72.9-169.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	104	138.6	75.0	(61.3-90.9)	Male	38	86.3	44.0	(31.2-60.5)
Female	46	56.2	81.8	(59.9-109.1)	Female	33	79.7	41.4	(28.5-58.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	18	27.6	65.1	(38.6-102.9)	Male	16	21.5	74.5	(42.6-121.1)
Female	18	25.7	70.1	(41.6-110.9)	Female	15	17.8	84.1	(47.1-138.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	6	4.3	138.6	(50.6-301.6)	Male	50	74.8	66.8	(49.6-88.1)
Female	520	540.2	96.3	(88.2-104.9)	Female	68	73.7	92.3	(71.7-117.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	40	24.4	164.0	(117.1-223.3)	Male	64	51.2	125.0	(96.2-159.6)
Female					Female	26	27.4	95.0	(62.1-139.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	165	193.0	85.5	(73.0-99.6)	Female	41	57.2	71.7	(51.5-97.3)
Female	174	204.3	85.2	(73.0-98.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	41	41.4	98.9	(71.0-134.2)
Male	33	35.2	93.6	(64.4-131.5)	Female	41	48.5	84.5	(60.6-114.6)
Female	7	10.9	64.2	(25.7-132.3)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	444	499.7	88.9	(80.8-97.5)
Male	13	13.8	94.2	(50.1-161.1)	<u>Stomach</u>				
Female	11	12.1	91.1	(45.4-163.1)	Male	48	32.0	150.0	(110.6-198.9)
<u>Kidney & Renal Pelvis</u>					Female	30	22.4	134.0	(90.4-191.4)
Male	65	64.1	101.4	(78.3-129.3)	<u>Testis</u>				
Female	51	44.6	114.4	(85.2-150.4)	Male	24	23.2	103.4	(66.2-153.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	28	21.7	129.3	(85.9-186.9)	Male	6	22.4	26.8	(9.8-58.4)
Female	8	6.5	122.9	(52.9-242.1)	Female	59	78.6	75.0	(57.1-96.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	33	48.2	68.4	(47.1-96.1)	Female	127	119.5	106.3	(88.6-126.4)
Female	31	41.4	74.9	(50.9-106.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1588	1824.8	87.0	(82.8-91.4)
Male	36	31.2	115.4	(80.8-159.8)	Female	1769	1927.1	91.8	(87.6-96.2)
Female	9	12.2	74.1	(33.8-140.6)					
<u>Lung and Bronchus</u>									
Male	241	253.6	95.0	(83.4-107.8)					
Female	267	269.7	99.0	(87.5-111.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	7.2	222.8	(127.3-361.9)	Male	5	5.0	100.2	(32.3-233.8)
Female	3	2.2	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	4.2	190.0	(81.8-374.3)
Female	27	27.0	99.8	(65.8-145.3)	Female	3	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	10.7	75.1	(32.3-148.0)	Female	2	2.7	nc	(nc-nc)
Female	3	8.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	2.3	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	Female	5	1.9	268.3	(86.5-626.2)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	28	29.2	95.8	(63.6-138.5)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.8	nc	(nc-nc)
Male	5	3.8	130.7	(42.1-305.1)	<u>Testis</u>				
Female	5	2.0	252.6	(81.4-589.5)	Male	0	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.5	nc	(nc-nc)	Female	2	5.9	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	96	102.4	93.7	(75.9-114.5)
Male	0	1.9	nc	(nc-nc)	Female	80	86.6	92.3	(73.2-114.9)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	13.7	58.6	(25.2-115.4)					
Female	10	10.9	91.9	(44.0-169.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.2	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	9	12.9	69.8	(31.9-132.6)	Female	2	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	5.7	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
Female	1	5.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	12	15.0	80.0	(41.3-139.8)
Male	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.5	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	38	52.7	72.1	(51.0-99.0)
Male	0	0.9	nc	(nc-nc)	Female	35	45.7	76.6	(53.4-106.6)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	7.7	90.5	(36.2-186.4)					
Female	4	6.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	30.0	136.5	(98.0-185.2)	Male	10	17.5	57.3	(27.4-105.3)
Female	10	11.8	84.6	(40.5-155.6)	Female	11	14.4	76.5	(38.1-136.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.0	119.6	(43.7-260.4)	Male	5	4.6	109.2	(35.2-254.8)
Female	5	4.5	111.8	(36.0-260.9)	Female	3	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	14	15.1	92.9	(50.7-155.9)
Female	103	104.5	98.5	(80.4-119.5)	Female	13	14.8	87.8	(46.7-150.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	4.2	216.2	(98.7-410.5)	Male	10	10.5	95.5	(45.7-175.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	44	41.1	107.0	(77.7-143.6)	Female	17	11.1	153.3	(89.2-245.4)
Female	50	43.1	116.1	(86.2-153.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	8.9	101.0	(46.1-191.8)
Male	10	7.5	133.3	(63.8-245.1)	Female	10	10.3	97.5	(46.7-179.4)
Female	2	2.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	122	107.6	113.4	(94.1-135.3)
Male	2	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.6	nc	(nc-nc)	Male	5	6.9	72.9	(23.5-170.0)
<u>Kidney & Renal Pelvis</u>					Female	5	4.8	105.1	(33.9-245.2)
Male	18	13.3	135.4	(80.2-214.1)	<u>Testis</u>				
Female	8	8.9	90.2	(38.8-177.7)	Male	4	3.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	4.6	130.0	(47.5-282.9)	Male	1	4.1	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	14	12.8	109.4	(59.8-183.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	9.3	149.8	(81.8-251.3)	Female	14	23.3	60.2	(32.9-101.0)
Female	6	7.9	75.9	(27.7-165.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	416	382.5	108.7	(98.5-119.7)
Male	10	6.5	154.1	(73.8-283.3)	Female	395	380.2	103.9	(93.9-114.7)
Female	2	2.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	57	54.8	104.1	(78.8-134.8)					
Female	66	55.8	118.3	(91.5-150.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	31.4	105.2	(72.4-147.8)	Male	21	19.4	108.2	(67.0-165.4)
Female	13	12.3	106.1	(56.4-181.5)	Female	19	16.4	115.9	(69.7-181.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.8	nc	(nc-nc)	Male	11	4.9	223.0	(111.2-399.0)
Female	5	5.0	99.1	(31.9-231.2)	Female	4	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	16	16.6	96.2	(55.0-156.3)
Female	112	118.7	94.4	(77.7-113.5)	Female	15	15.8	95.0	(53.1-156.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	5.0	201.7	(96.6-370.9)	Male	23	12.1	189.9	(120.3-284.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	52	44.1	117.9	(88.0-154.6)	Female	17	12.4	137.3	(79.9-219.8)
Female	54	44.2	122.2	(91.8-159.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	9.5	146.7	(80.2-246.2)
Male	18	8.3	217.9	(129.1-344.4)	Female	11	10.5	104.4	(52.0-186.7)
Female	4	2.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	123	119.5	102.9	(85.5-122.8)
Male	1	2.4	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.0	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	4.8	nc	(nc-nc)
Male	8	14.9	53.8	(23.2-106.0)	<u>Testis</u>				
Female	14	9.7	144.3	(78.8-242.2)	Male	6	4.0	149.2	(54.5-324.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	5.1	156.2	(67.2-307.7)	Male	11	4.9	225.3	(112.3-403.2)
Female	1	1.5	nc	(nc-nc)	Female	17	15.6	109.2	(63.5-174.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	10.2	49.0	(15.8-114.4)	Female	24	26.8	89.5	(57.4-133.2)
Female	8	8.4	95.8	(41.2-188.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	457	418.2	109.3	(99.5-119.8)
Male	6	7.3	81.7	(29.8-177.8)	Female	471	415.9	113.3	(103.3-124.0)
Female	2	2.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	62	58.5	105.9	(81.2-135.8)					
Female	74	59.3	124.7	(97.9-156.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	5.3	133.2	(53.4-274.5)	Male	8	3.9	206.4	(88.9-406.7)
Female	3	1.8	nc	(nc-nc)	Female	9	3.2	283.6	(129.4-538.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.2	216.9	(86.9-446.9)
Female	32	22.8	140.5	(96.1-198.3)	Female	1	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	8.0	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
Female	9	6.6	135.9	(62.0-258.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	1.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	29	23.8	122.0	(81.7-175.2)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	3.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.9	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	3.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.5	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	5	10.4	48.2	(15.5-112.6)	Male	78	79.6	97.9	(77.4-122.2)
Female	9	9.2	97.6	(44.5-185.3)	Female	86	72.6	118.4	(94.7-146.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.0	99.5	(47.7-183.1)	Male	2	6.3	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	6	4.9	123.6	(45.1-269.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.9	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.4	111.0	(40.5-241.6)
Female	31	34.8	89.0	(60.5-126.3)	Female	6	4.4	135.0	(49.3-293.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	14.3	98.1	(53.6-164.6)	Female	2	3.6	nc	(nc-nc)
Female	10	12.1	82.4	(39.5-151.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.1	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	25	38.9	64.3	(41.6-94.9)
Male	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.3	nc	(nc-nc)
Male	2	4.9	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.7	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	8	4.8	165.8	(71.4-326.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.3	nc	(nc-nc)	Female	7	7.8	89.9	(36.0-185.3)
Female	3	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	104	135.6	76.7	(62.6-92.9)
Male	1	2.4	nc	(nc-nc)	Female	114	119.0	95.8	(79.0-115.1)
Female	1	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	18.8	85.0	(48.5-138.0)					
Female	17	16.6	102.5	(59.7-164.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	16.0	131.1	(81.1-200.5)	Male	17	11.1	153.7	(89.5-246.1)
Female	9	5.4	168.0	(76.7-319.0)	Female	9	8.7	103.1	(47.1-195.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	3.5	226.1	(97.4-445.6)	Male	4	2.7	nc	(nc-nc)
Female	5	2.8	180.1	(58.1-420.4)	Female	3	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	16	9.3	172.0	(98.3-279.4)
Female	69	63.5	108.7	(84.6-137.6)	Female	9	7.4	122.2	(55.8-232.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.9	nc	(nc-nc)	Male	4	7.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	23.7	105.4	(68.2-155.7)	Female	2	6.4	nc	(nc-nc)
Female	23	19.6	117.5	(74.5-176.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	5.1	nc	(nc-nc)
Male	1	4.6	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	77	67.2	114.6	(90.4-143.2)
Male	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.1	nc	(nc-nc)	Male	5	3.7	133.6	(43.1-311.9)
<u>Kidney & Renal Pelvis</u>					Female	0	2.1	nc	(nc-nc)
Male	6	8.6	70.1	(25.6-152.6)	<u>Testis</u>				
Female	3	4.7	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	2.9	nc	(nc-nc)	Male	5	3.0	164.8	(53.1-384.5)
Female	1	0.7	nc	(nc-nc)	Female	7	9.3	75.3	(30.2-155.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	5.6	106.3	(38.8-231.3)	Female	15	14.1	106.7	(59.7-176.0)
Female	6	4.1	146.2	(53.4-318.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	244	230.1	106.0	(93.2-120.2)
Male	2	4.3	nc	(nc-nc)	Female	203	205.7	98.7	(85.6-113.2)
Female	1	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	30.9	71.3	(44.7-108.0)					
Female	19	26.5	71.6	(43.1-111.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.3	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	8	10.0	80.0	(34.4-157.6)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	3.5	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	7	3.6	194.0	(77.7-399.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	10	9.0	110.5	(52.9-203.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.4	nc	(nc-nc)	Male	29	34.0	85.2	(57.0-122.3)
Female	1	0.1	nc	(nc-nc)	Female	30	35.5	84.5	(57.0-120.6)
<u>Leukemia</u>									
Male	0	0.9	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	0.6	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	4.4	nc	(nc-nc)					
Female	1	4.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.6	66.2	(21.3-154.5)	Male	4	5.4	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.6	109.6	(35.3-255.8)
Female	31	28.9	107.4	(73.0-152.5)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	5	3.6	139.3	(44.9-325.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	11.4	87.8	(42.0-161.5)	Female	3	2.9	nc	(nc-nc)
Female	8	8.3	96.2	(41.4-189.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	2.4	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	27	31.6	85.4	(56.3-124.3)
Male	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.9	nc	(nc-nc)
Male	6	4.1	145.4	(53.1-316.4)	<u>Testis</u>				
Female	3	2.1	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.8	nc	(nc-nc)	Female	2	6.4	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	104	110.2	94.4	(77.1-114.4)
Male	1	2.1	nc	(nc-nc)	Female	98	92.6	105.9	(86.0-129.0)
Female	0	0.5	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	12	14.4	83.4	(43.0-145.7)	<u>Bladder, Urinary</u>				
Female	21	11.6	180.8	(111.9-276.3)	Male	5	7.6	66.2	(21.3-154.5)
<u>Lung and Bronchus</u>					Female	2	2.3	nc	(nc-nc)
Male	12	14.4	83.4	(43.0-145.7)	<u>Brain and Other Nervous System</u>				
Female	21	11.6	180.8	(111.9-276.3)	Male	2	1.7	nc	(nc-nc)
<u>Lung and Bronchus</u>					Female	3	1.3	nc	(nc-nc)
Male	12	14.4	83.4	(43.0-145.7)	<u>Breast</u>				
Female	21	11.6	180.8	(111.9-276.3)	Male	0	0.3	nc	(nc-nc)
<u>Lung and Bronchus</u>					Female	31	28.9	107.4	(73.0-152.5)
Male	12	14.4	83.4	(43.0-145.7)	<u>Cervix Uteri</u>				
Female	21	11.6	180.8	(111.9-276.3)	Female	1	1.5	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Colon / Rectum</u>				
Male	12	14.4	83.4	(43.0-145.7)	Male	10	11.4	87.8	(42.0-161.5)
Female	21	11.6	180.8	(111.9-276.3)	Female	8	8.3	96.2	(41.4-189.6)
<u>Lung and Bronchus</u>					<u>Esophagus</u>				
Male	12	14.4	83.4	(43.0-145.7)	Male	0	2.2	nc	(nc-nc)
Female	21	11.6	180.8	(111.9-276.3)	Female	0	0.4	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Hodgkin Lymphoma</u>				
Male	12	14.4	83.4	(43.0-145.7)	Male	1	0.8	nc	(nc-nc)
Female	21	11.6	180.8	(111.9-276.3)	Female	1	0.6	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Kidney & Renal Pelvis</u>				
Male	12	14.4	83.4	(43.0-145.7)	Male	6	4.1	145.4	(53.1-316.4)
Female	21	11.6	180.8	(111.9-276.3)	Female	3	2.1	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Larynx</u>				
Male	12	14.4	83.4	(43.0-145.7)	Male	2	1.4	nc	(nc-nc)
Female	21	11.6	180.8	(111.9-276.3)	Female	0	0.3	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Leukemia</u>				
Male	12	14.4	83.4	(43.0-145.7)	Male	3	2.8	nc	(nc-nc)
Female	21	11.6	180.8	(111.9-276.3)	Female	2	1.8	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	12	14.4	83.4	(43.0-145.7)	Male	1	2.1	nc	(nc-nc)
Female	21	11.6	180.8	(111.9-276.3)	Female	0	0.5	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Lung and Bronchus</u>				
Male	12	14.4	83.4	(43.0-145.7)	Male	12	14.4	83.4	(43.0-145.7)
Female	21	11.6	180.8	(111.9-276.3)	Female	21	11.6	180.8	(111.9-276.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	19.8	60.8	(31.4-106.1)	Male	21	11.4	183.6	(113.6-280.6)
Female	7	7.7	91.0	(36.5-187.6)	Female	23	9.5	241.4	(152.9-362.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	5	3.0	166.1	(53.5-387.6)
Female	4	3.0	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	13	9.9	131.0	(69.7-224.1)
Female	67	69.4	96.5	(74.8-122.5)	Female	12	9.7	123.1	(63.5-215.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.8	nc	(nc-nc)	Male	2	6.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	27.1	84.8	(53.7-127.2)	Female	10	7.3	136.2	(65.2-250.4)
Female	27	28.9	93.6	(61.6-136.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	5.8	153.9	(70.2-292.1)
Male	2	4.9	nc	(nc-nc)	Female	7	6.8	103.3	(41.4-212.9)
Female	1	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	72	68.5	105.2	(82.3-132.5)
Male	3	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	3.2	nc	(nc-nc)
Male	8	8.6	93.0	(40.0-183.2)	<u>Testis</u>				
Female	4	5.7	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.0	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	10	8.5	118.0	(56.5-217.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	6.2	274.4	(159.7-439.3)	Female	14	15.2	92.3	(50.4-154.8)
Female	6	5.3	113.1	(41.3-246.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	256	248.0	103.2	(91.0-116.7)
Male	1	4.2	nc	(nc-nc)	Female	257	250.5	102.6	(90.4-115.9)
Female	1	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	29	35.1	82.6	(55.3-118.6)					
Female	28	35.5	79.0	(52.5-114.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	20.3	127.9	(83.5-187.4)	Male	11	12.5	88.0	(43.9-157.5)
Female	10	7.4	134.8	(64.5-247.9)	Female	9	9.9	91.0	(41.5-172.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.7	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	7	10.7	65.3	(26.2-134.6)
Female	55	72.0	76.4	(57.5-99.4)	Female	15	9.6	156.9	(87.8-258.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	6	7.8	76.7	(28.0-167.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	28.6	94.4	(62.2-137.4)	Female	5	7.5	66.6	(21.5-155.5)
Female	37	26.8	137.9	(97.1-190.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	4	5.3	nc	(nc-nc)	Male	7	6.2	113.3	(45.4-233.5)
Female	0	1.4	nc	(nc-nc)	Female	8	6.4	124.9	(53.8-246.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.5	nc	(nc-nc)	Male	73	76.8	95.0	(74.5-119.5)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	7	9.6	73.3	(29.4-151.0)	Male	4	4.7	nc	(nc-nc)
Female	10	5.9	170.0	(81.4-312.7)	Female	2	2.9	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	3.3	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	6.5	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	5	5.0	99.7	(32.1-232.6)	Female	10	9.4	106.9	(51.2-196.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.8	105.1	(33.9-245.4)	Female	16	16.2	98.7	(56.4-160.3)
Female	3	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	52	37.7	137.9	(103.0-180.9)	Male	271	269.5	100.6	(88.9-113.3)
Female	32	36.0	88.9	(60.8-125.5)	Female	250	251.8	99.3	(87.4-112.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	65	54.9	118.5	(91.5-151.0)	Male	15	35.3	42.5	(23.8-70.2)
Female	17	21.8	78.1	(45.5-125.0)	Female	22	31.0	71.1	(44.5-107.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	10.9	91.5	(43.8-168.2)	Male	11	8.7	126.9	(63.3-227.2)
Female	9	9.7	93.2	(42.5-177.0)	Female	9	6.9	130.2	(59.4-247.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.8	nc	(nc-nc)	Male	27	30.1	89.7	(59.1-130.5)
Female	190	211.1	90.0	(77.7-103.8)	Female	35	28.6	122.5	(85.3-170.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	13	9.6	134.9	(71.8-230.7)	Male	28	21.4	130.9	(87.0-189.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	76	77.5	98.0	(77.2-122.7)	Female	22	22.2	99.3	(62.2-150.3)
Female	78	79.6	98.0	(77.5-122.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	21	16.6	126.1	(78.1-192.8)
Male	13	14.4	90.3	(48.0-154.4)	Female	20	18.8	106.3	(64.9-164.3)
Female	4	4.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	190	207.1	91.7	(79.2-105.8)
Male	6	5.2	116.5	(42.5-253.5)	<u>Stomach</u>				
Female	5	4.3	115.7	(37.3-270.1)	Male	26	12.7	204.7	(133.7-300.0)
<u>Kidney & Renal Pelvis</u>					Female	12	8.8	136.9	(70.7-239.2)
Male	31	26.5	117.2	(79.6-166.4)	<u>Testis</u>				
Female	17	17.2	98.6	(57.4-157.8)	Male	10	9.3	108.1	(51.7-198.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	15	8.9	167.9	(93.9-276.9)	Male	8	9.3	85.6	(36.8-168.6)
Female	1	2.5	nc	(nc-nc)	Female	31	30.5	101.5	(69.0-144.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	18.7	58.9	(29.4-105.4)	Female	43	46.7	92.1	(66.6-124.0)
Female	14	15.8	88.7	(48.4-148.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	783	739.5	105.9	(98.6-113.6)
Male	16	12.8	124.6	(71.2-202.4)	Female	725	748.3	96.9	(90.0-104.2)
Female	5	4.7	106.2	(34.2-247.9)					
<u>Lung and Bronchus</u>									
Male	130	102.0	127.4	(106.5-151.3)					
Female	121	104.0	116.3	(96.5-139.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.8	nc	(nc-nc)	Male	7	5.1	136.7	(54.8-281.7)
Female	1	2.7	nc	(nc-nc)	Female	0	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	4.4	nc	(nc-nc)
Female	23	27.4	84.0	(53.3-126.1)	Female	3	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	11.3	88.6	(42.4-163.0)	Female	7	2.8	246.3	(98.7-507.5)
Female	8	10.0	80.4	(34.6-158.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.4	nc	(nc-nc)
Male	5	2.1	233.9	(75.4-545.8)	Female	2	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	30	30.9	97.0	(65.4-138.4)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	1.1	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.6	nc	(nc-nc)	Female	11	6.0	182.1	(90.8-325.9)
Female	3	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	96	108.0	88.9	(72.0-108.6)
Male	1	1.9	nc	(nc-nc)	Female	87	95.1	91.5	(73.3-112.9)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	14.8	142.0	(87.9-217.1)					
Female	11	13.1	83.7	(41.7-149.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	29.1	82.5	(52.9-122.8)	Male	21	19.4	108.3	(67.0-165.6)
Female	21	10.4	201.0	(124.4-307.2)	Female	16	15.8	101.2	(57.8-164.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	6.0	nc	(nc-nc)	Male	6	4.7	127.0	(46.4-276.4)
Female	5	4.9	102.1	(32.9-238.3)	Female	1	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	17	16.4	103.8	(60.4-166.2)
Female	106	112.6	94.1	(77.0-113.8)	Female	17	13.9	121.9	(71.0-195.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.1	116.9	(42.7-254.4)	Male	16	12.3	129.7	(74.1-210.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	47	42.0	111.8	(82.1-148.7)	Female	13	11.5	113.0	(60.1-193.2)
Female	39	37.2	104.9	(74.6-143.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	19	9.0	210.2	(126.5-328.2)
Male	7	8.0	87.4	(35.0-180.0)	Female	15	8.9	169.2	(94.6-279.0)
Female	0	2.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	119	117.7	101.1	(83.7-121.0)
Male	4	2.6	nc	(nc-nc)	<u>Stomach</u>				
Female	2	2.0	nc	(nc-nc)	Male	3	6.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	6	3.9	152.4	(55.7-331.8)
Male	16	14.8	108.0	(61.7-175.4)	<u>Testis</u>				
Female	14	8.9	158.2	(86.4-265.4)	Male	6	4.6	130.4	(47.6-283.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	5.0	nc	(nc-nc)	Male	5	5.2	95.4	(30.8-222.7)
Female	1	1.3	nc	(nc-nc)	Female	24	16.3	147.2	(94.3-219.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	9.9	nc	(nc-nc)	Female	28	25.5	109.9	(73.0-158.9)
Female	13	7.5	173.8	(92.5-297.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	436	406.7	107.2	(97.4-117.7)
Male	12	7.3	164.3	(84.8-286.9)	Female	439	379.3	115.7	(105.2-127.1)
Female	2	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	73	55.3	131.9	(103.4-165.8)					
Female	68	52.1	130.5	(101.3-165.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.9	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	Female	10	2.6	380.6	(182.2-699.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	29	19.3	150.0	(100.4-215.4)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	6.8	88.1	(32.2-191.8)	Female	2	2.1	nc	(nc-nc)
Female	9	8.0	112.6	(51.4-213.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	28	17.4	160.6	(106.7-232.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.2	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.8	nc	(nc-nc)	Male	81	63.0	128.5	(102.1-159.7)
Female	0	0.2	nc	(nc-nc)	Female	88	70.2	125.4	(100.6-154.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	1.4	nc	(nc-nc)	Male	81	63.0	128.5	(102.1-159.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.1	nc	(nc-nc)	Female	88	70.2	125.4	(100.6-154.5)
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	17	8.9	190.1	(110.7-304.3)	Male	81	63.0	128.5	(102.1-159.7)
Female	14	10.3	136.3	(74.4-228.7)	Female	88	70.2	125.4	(100.6-154.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	2.8	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	2	8.9	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	1	5.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.2	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	8.2	nc	(nc-nc)	Male	10	4.9	203.8	(97.5-374.7)
Female	3	2.7	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	4	1.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
Female	34	26.9	126.4	(87.5-176.7)	Female	1	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	11.4	43.7	(14.1-102.1)	Female	2	2.8	nc	(nc-nc)
Female	18	9.7	186.1	(110.3-294.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.5	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	34	30.9	110.1	(76.2-153.8)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.0	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.6	nc	(nc-nc)	Female	4	6.0	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	92	107.4	85.6	(69.0-105.0)
Male	3	1.9	nc	(nc-nc)	Female	98	92.5	106.0	(86.0-129.1)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	15.2	52.6	(22.7-103.7)					
Female	5	13.1	38.1	(12.3-88.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	6.2	193.6	(99.9-338.3)	Male	5	4.9	102.0	(32.9-238.0)
Female	3	2.3	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.1	171.3	(68.6-352.9)
Female	30	28.9	103.9	(70.1-148.3)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	9.7	113.9	(56.8-203.9)	Female	1	2.9	nc	(nc-nc)
Female	8	8.4	95.4	(41.1-187.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.9	nc	(nc-nc)	Male	28	26.5	105.6	(70.2-152.7)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.7	nc	(nc-nc)	Female	6	6.2	97.5	(35.6-212.3)
Female	0	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.2	nc	(nc-nc)	Male	108	94.8	113.9	(93.5-137.6)
Female	0	0.3	nc	(nc-nc)	Female	86	92.6	92.9	(74.3-114.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.5	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	13	12.0	108.3	(57.6-185.2)	<u>All Sites / Types</u>				
Female	14	11.5	122.2	(66.7-205.0)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.3	152.4	(49.1-355.6)	Male	1	1.9	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	10	11.1	90.2	(43.2-166.0)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	4.6	131.8	(48.1-287.0)	Female	1	1.1	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	20	12.0	166.6	(101.7-257.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.5	nc	(nc-nc)	Female	0	2.5	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	0.5	nc	(nc-nc)	Male	63	42.2	149.4	(114.8-191.2)
Female	0	0.1	nc	(nc-nc)	Female	29	37.7	76.9	(51.5-110.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	6.0	165.9	(79.4-305.2)	<u>All Sites / Types</u>				
Female	3	5.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.5	119.7	(54.6-227.3)	Male	4	5.8	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	7	5.1	137.3	(55.0-282.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	44	33.7	130.4	(94.8-175.1)	Female	5	3.9	129.1	(41.6-301.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	7	3.7	188.8	(75.6-388.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	11.5	165.2	(99.4-258.0)	Female	2	3.4	nc	(nc-nc)
Female	8	9.8	81.9	(35.2-161.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.4	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	Female	8	2.3	351.1	(151.2-691.9)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	30.9	106.9	(73.6-150.2)
Male	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	1.0	nc	(nc-nc)
Male	1	4.4	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	5	5.9	85.3	(27.5-199.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.0	nc	(nc-nc)	Female	7	7.2	96.6	(38.7-199.0)
Female	3	2.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	127	112.4	113.0	(94.2-134.4)
Male	2	2.1	nc	(nc-nc)	Female	122	109.0	111.9	(92.9-133.6)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	14.4	152.6	(95.6-231.1)					
Female	16	13.5	118.8	(67.9-192.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	2.4	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	8	7.9	101.8	(43.8-200.6)
Male	0	0.1	nc	(nc-nc)	Female	3	6.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.1	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.0	160.9	(69.3-317.1)	Male	3	3.6	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	22	21.4	102.8	(64.4-155.7)	Female	1	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	7.5	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
Female	12	7.1	168.2	(86.8-293.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.6	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	26	20.3	128.1	(83.6-187.7)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.8	nc	(nc-nc)
Male	5	2.7	182.9	(58.9-426.9)	<u>Testis</u>				
Female	1	1.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	6	3.4	176.1	(64.3-383.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.8	nc	(nc-nc)	Female	7	4.6	153.1	(61.3-315.4)
Female	4	1.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	73	72.3	101.0	(79.2-127.0)
Male	1	1.4	nc	(nc-nc)	Female	83	72.0	115.3	(91.9-143.0)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	9.4	74.2	(29.7-153.0)					
Female	5	9.3	53.7	(17.3-125.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	9.5	158.1	(88.4-260.7)	Male	7	6.7	104.0	(41.7-214.4)
Female	7	3.8	184.1	(73.7-379.3)	Female	4	6.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.2	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.7	123.2	(49.4-253.9)
Female	46	40.6	113.4	(83.0-151.2)	Female	8	5.1	155.9	(67.1-307.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.0	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	13.9	143.6	(87.7-221.8)	Female	7	4.2	168.1	(67.4-346.5)
Female	17	13.9	122.5	(71.3-196.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	3.0	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	45	37.7	119.3	(87.0-159.7)
Male	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.5	nc	(nc-nc)
Male	3	5.0	nc	(nc-nc)	<u>Testis</u>				
Female	6	3.2	189.2	(69.1-411.9)	Male	4	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.6	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	8	6.4	125.0	(53.8-246.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.5	nc	(nc-nc)	Female	11	8.8	125.5	(62.6-224.7)
Female	3	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	150	135.3	110.8	(93.8-130.1)
Male	2	2.5	nc	(nc-nc)	Female	163	138.7	117.5	(100.2-137.0)
Female	1	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	18.0	110.8	(67.7-171.2)					
Female	24	18.5	130.0	(83.3-193.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	28.7	80.1	(50.8-120.2)	Male	17	17.7	96.0	(55.9-153.8)
Female	16	11.5	139.1	(79.4-225.9)	Female	19	15.0	126.3	(76.0-197.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.3	113.7	(41.5-247.4)	Male	8	4.5	179.1	(77.1-352.9)
Female	3	4.7	nc	(nc-nc)	Female	5	3.7	136.7	(44.1-319.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	18	15.2	118.8	(70.4-187.7)
Female	111	107.1	103.7	(85.3-124.8)	Female	13	14.7	88.2	(46.9-150.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.5	110.2	(35.5-257.2)	Male	4	10.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	38	40.1	94.7	(67.0-130.1)	Female	14	11.3	124.3	(67.9-208.6)
Female	31	42.3	73.2	(49.7-103.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	8.6	69.4	(25.3-151.0)
Male	5	7.4	67.4	(21.7-157.3)	Female	6	10.0	59.9	(21.9-130.3)
Female	1	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	116	105.5	110.0	(90.9-131.9)
Male	1	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.8	nc	(nc-nc)	Male	6	6.6	90.8	(33.1-197.5)
<u>Kidney & Renal Pelvis</u>					Female	8	4.7	171.0	(73.6-336.9)
Male	12	13.4	89.3	(46.1-155.9)	<u>Testis</u>				
Female	7	8.9	79.0	(31.7-162.9)	Male	2	3.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	4.6	109.9	(35.4-256.4)	Male	7	4.5	156.8	(62.8-323.1)
Female	1	1.3	nc	(nc-nc)	Female	13	14.1	92.3	(49.1-157.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	9.3	96.6	(44.1-183.4)	Female	19	23.5	80.9	(48.7-126.4)
Female	8	8.0	99.9	(43.0-196.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	368	377.1	97.6	(87.9-108.1)
Male	10	6.6	151.9	(72.7-279.4)	Female	367	382.6	95.9	(86.3-106.2)
Female	3	2.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	37	53.1	69.7	(49.1-96.1)					
Female	47	54.3	86.5	(63.6-115.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	10	6.5	154.1	(73.8-283.5)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	2.2	nc	(nc-nc)	Female	3	0.6	nc	(nc-nc)
Female	5	1.8	283.0	(91.2-660.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	5	6.6	75.8	(24.4-176.9)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Thyroid</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.5	nc	(nc-nc)	Male	27	22.0	122.7	(80.8-178.5)
Female	0	0.4	nc	(nc-nc)	Female	25	20.3	123.0	(79.6-181.6)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	1	0.4	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	2.8	178.6	(57.6-416.9)					
Female	3	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;